## Shinji Saiki

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7052814/publications.pdf

Version: 2024-02-01

|                |                   | 331259             | 344852                  |
|----------------|-------------------|--------------------|-------------------------|
| 37             | 5,450 citations   | 21                 | 36                      |
| papers         | citations         | h-index            | g-index                 |
|                |                   |                    |                         |
|                |                   |                    |                         |
| 27             | 27                | 27                 | 10240                   |
| 3/             | 3/                | 3/                 | 10349                   |
| all docs       | docs citations    | times ranked       | citing authors          |
|                |                   |                    |                         |
| 37<br>all docs | 37 docs citations | 37<br>times ranked | 10349<br>citing authors |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. Journal of Cell Biology, 2010, 189, 211-221.                    | 2.3 | 1,600     |
| 2  | Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nature Chemical Biology, 2008, 4, 295-305.   | 3.9 | 739       |
| 3  | Lysosomal positioning coordinates cellular nutrient responses. Nature Cell Biology, 2011, 13, 453-460.  | 4.6 | 726       |
| 4  | Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy, 2011, 7, 176-187.  | 4.3 | 385       |
| 5  | Huntington's disease: from pathology and genetics to potential therapies. Biochemical Journal, 2008, 412, 191-209.  | 1.7 | 373       |
| 6  | A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Human Molecular Genetics, 2008, 17, 170-178.  | 1.4 | 312       |
| 7  | Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 295-301.                                       | 0.9 | 214       |
| 8  | PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Letters, 2010, 584, 1073-1079.  | 1.3 | 205       |
| 9  | Symbiotic polyamine metabolism regulates epithelial proliferation and macrophage differentiation in the colon. Nature Communications, 2021, 12, 2105.   | 5.8 | 105       |
| 10 | Decreased long-chain acylcarnitines from insufficient $\hat{l}^2$ -oxidation as potential early diagnostic markers for Parkinsonâ $\in$ <sup>TM</sup> s disease. Scientific Reports, 2017, 7, 7328. | 1.6 | 95        |
| 11 | A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of Neurology, 2019, 86, 251-263.  | 2.8 | 74        |
| 12 | Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology, 2018, 90, e404-e411.  | 1.5 | 70        |
| 13 | Molecular pathogenesis of Parkinson's disease: update. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 430-436.  | 0.9 | 69        |
| 14 | Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. Journal of Neuroscience, 2020, 40, 8618-8628.  | 1.7 | 57        |
| 15 | Connectome analysis with diffusion MRI in idiopathic Parkinson's disease: Evaluation using multi-shell, multi-tissue, constrained spherical deconvolution. NeuroImage: Clinical, 2018, 17, 518-529. | 1.4 | 51        |
| 16 | Metabolomicsâ€based identification of metabolic alterations in PARK2. Annals of Clinical and Translational Neurology, 2019, 6, 525-536.   | 1.7 | 44        |
| 17 | Regulation by mitophagy. International Journal of Biochemistry and Cell Biology, 2014, 53, 147-150.   | 1.2 | 40        |
| 18 | Extensive hemispheric lesions with radiological evidence of blood–brain barrier integrity in a patient with neuromyelitis optica. Journal of the Neurological Sciences, 2009, 284, 217-219.         | 0.3 | 39        |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Neuroprotective effects of memantine via enhancement of autophagy. Biochemical and Biophysical Research Communications, 2019, 518, 161-170.   | 1.0 | 36        |
| 20 | Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neuroscience Letters, 2010, 481, 88-91.  | 1.0 | 27        |
| 21 | Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. Annals of Clinical and Translational Neurology, 2020, 7, 307-317.   | 1.7 | 22        |
| 22 | A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers. Autophagy, 2021, 17, 1856-1872.  | 4.3 | 20        |
| 23 | Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a<br>pilot study. Neurological Sciences, 2021, 42, 4767-4770.                                  | 0.9 | 19        |
| 24 | p150glued deficiency impairs effective fusion between autophagosomes and lysosomes due to their redistribution to the cell periphery. Neuroscience Letters, 2019, 690, 181-187.                 | 1.0 | 15        |
| 25 | p150glued-Associated Disorders Are Caused by Activation of Intrinsic Apoptotic Pathway. PLoS ONE, 2014, 9, e94645.  | 1.1 | 14        |
| 26 | Ethambutol neutralizes lysosomes and causes lysosomal zinc accumulation. Biochemical and Biophysical Research Communications, 2016, 471, 109-116.   | 1.0 | 14        |
| 27 | Non-invasive diagnostic tool for Parkinson's disease by sebum RNA profile with machine learning.<br>Scientific Reports, 2021, 11, 18550.  | 1.6 | 14        |
| 28 | Metabolomic analysis revealed mitochondrial dysfunction and aberrant choline metabolism in MPP+-exposed SH-SY5Y cells. Biochemical and Biophysical Research Communications, 2019, 519, 540-546. | 1.0 | 13        |
| 29 | Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up. Parkinsonism and Related Disorders, 2021, 84, 139-143.              | 1.1 | 12        |
| 30 | Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.<br>Movement Disorders, 2021, 36, 1759-1771.  | 2.2 | 10        |
| 31 | Immunocytochemical Monitoring of PINK1/Parkin-Mediated Mitophagy in Cultured Cells. Methods in Molecular Biology, 2017, 1759, 19-27.  | 0.4 | 9         |
| 32 | Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. PLoS ONE, 2019, 14, e0223113.  | 1.1 | 9         |
| 33 | Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Movement Disorders, 2020, 35, 1438-1447.  | 2.2 | 8         |
| 34 | Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells, 2019, 8, 14.   | 1.8 | 5         |
| 35 | Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis.<br>Scientific Reports, 2022, 12, .   | 1.6 | 3         |
| 36 | Metabolomic analysis data of MPP+-exposed SH-SY5Y cells using CE-TOFMS. Data in Brief, 2021, 34, 106707.  | 0.5 | 1         |

| #  | Article  | lF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Diffusion MRI Captures White Matter Microstructure Alterations in PRKN Disease. Journal of Parkinson's Disease, 2021, 11, 1221-1235. | 1.5 | 1         |